Avalo Therapeutics grants director 1,352 options

The options have a $15.33 exercise price and expire on September 30, 2036.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. director Kevin Robert Lind received 1,352 stock options on September 30, 2026. The award was 100% vested and was issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. Lind's reported post-transaction option position was 1,352.

Insider Trade Summary

Grant/Award: 1,352 shares

Grant/Award 1 txn

Insider Lind Kevin Robert

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F2, F1	1,352	$12.29	$17K

Holdings After Transaction: Stock Option (Right to Buy) — 1,352 contracts (Direct)

Footnotes (2)

1. F1. The options were granted on September 30, 2026, and are 100% vested.
2. F2. The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.

Key Figures

Stock options awarded: 1,352 options Vesting: 100% Exercise price: $15.33 per share +2 more

5 metrics

Stock options awarded 1,352 options Granted September 30, 2026

Vesting 100% The options were 100% vested when granted

Exercise price $15.33 per share Stock options

Expiration date September 30, 2036 Stock options

Post-transaction option position 1,352 options Reported after the September 30, 2026 award

Key Terms

Stock Option (Right to Buy), vested, Amended and Restated Non-Employee Director Compensation Plan

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vested financial

"are 100% vested"

Amended and Restated Non-Employee Director Compensation Plan financial

"pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the AVTX option award's exercise price and expiration date?

The options have an exercise price of $15.33 per share and expire on September 30, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:16 PM Accepted by SEC EDGAR 10/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lind Kevin Robert

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.33	09/30/2026		A		1,352		(1)	09/30/2036	Common Stock	1,352	$12.29(2)	1,352	D

Explanation of Responses:

1. The options were granted on September 30, 2026, and are 100% vested.

2. The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.

	/s/ Christopher Sullivan, Attorney-in-Fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)